Mariam Ansar (@mariamansar1) 's Twitter Profile
Mariam Ansar

@mariamansar1

IM Resident PGY-2 Cooper University Hospital 👩‍⚕️ | Marathon Runner 🏃‍♀️ | Aspiring Cardiologist 🫀

ID: 1479956794902417409

calendar_today08-01-2022 23:23:16

216 Tweet

593 Followers

569 Following

Qasem Ahmed (@qalmulihi) 's Twitter Profile Photo

Vasopressors and Inotropes - Summary Sheet 1️⃣ Norepinephrine (Levo) 💉 Action: α1 > β1 agonist → ↑↑ SVR, ↑ CO, reflex brady may negate ↑ HR 📌 Uses: Septic shock (1st), Cardiogenic shock (1st), Hypovolemic shock (1st) 2️⃣ Phenylephrine (Neo) 💉 Action: Pure α1 agonist →

Vasopressors and Inotropes - Summary Sheet

1️⃣ Norepinephrine (Levo)
💉 Action: α1 > β1 agonist → ↑↑ SVR, ↑ CO, reflex brady may negate ↑ HR
📌 Uses: Septic shock (1st), Cardiogenic shock (1st), Hypovolemic shock (1st)

2️⃣ Phenylephrine (Neo)
💉 Action: Pure α1 agonist →
Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

Here’s my guide to navigate the #ACC25 trials, coming this weekend and featured in many journals with a (very) high impact factor. 1. WARRIOR = Intensive medical therapy in women with ANOCA/INOCA 2. STRIDE = Semaglutide in type 2 diabetes and peripheral artery disease 3. API-CAT

Here’s my guide to navigate the #ACC25 trials, coming this weekend and featured in many journals with a (very) high impact factor.

1. WARRIOR = Intensive medical therapy in women with ANOCA/INOCA
2. STRIDE = Semaglutide in type 2 diabetes and peripheral artery disease
3. API-CAT
Alfonso Valle (@vallealfonso) 's Twitter Profile Photo

1/ 🔬#Semaglutide & #CardiovascularRisk in #T2D! The SOUL trial, published in NEJM, assessed its efficacy in high-risk patients with #ASCVD or #CKD. 🚨 Results? A significant reduction in MACE! #ACC25 #HeartHealth 2/ 📊 In this large RCT (N=9,650), oral semaglutide (14 mg/day)

1/ 🔬#Semaglutide &amp; #CardiovascularRisk in #T2D! The SOUL trial, published in <a href="/NEJM/">NEJM</a>, assessed its efficacy in high-risk patients with #ASCVD or #CKD. 
🚨 Results? A significant reduction in MACE! #ACC25 #HeartHealth

2/ 📊 In this large RCT (N=9,650), oral semaglutide (14 mg/day)
Cristobal Morales (@cristobmorales) 's Twitter Profile Photo

nejm.org/doi/full/10.10… Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) NEJM lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated

Mariam Ansar (@mariamansar1) 's Twitter Profile Photo

Final WINNERS at ACC Fitness Center Jeopardy this andrew!! 🫀💯💯 Missouri ACC Big congratulations to the team for bringing fire to the stage🔥🔥 Kudos to ALL teams for qualifying and playing so well. You all made this seem so much fun 🤩 Special thanks to our hosts, moderators, and

Final WINNERS at <a href="/ACCFIT/">ACC Fitness Center</a> Jeopardy this <a href="/ACC25/">andrew</a>!! 🫀💯💯 <a href="/MissouriACC/">Missouri ACC</a> 
Big congratulations to the team for bringing fire to the stage🔥🔥

Kudos to ALL teams for qualifying and playing so well. You all made this seem so much fun 🤩 

Special thanks to our hosts, moderators, and
Shikha Jha M.D.🫀 (@shikha_cardio) 's Twitter Profile Photo

ACC 2025 LATE BREAKING CLINICAL TRIALS - One LINER SUMMARY 📸 AT A GLANCE ⭐️ What a phenomenal scientific meeting! Congratulations to all the presenters &research leaders for yet another fantastic year of innovation & research. 🫀❤️ 😊 #ACC2025 American College of Cardiology UW-Madison Division of Cardiovascular Medicine CardioNerds

ACC 2025  LATE BREAKING CLINICAL TRIALS - One LINER SUMMARY 📸 AT A GLANCE ⭐️ What a phenomenal scientific meeting! Congratulations to all the presenters &amp;research leaders for yet another fantastic year of innovation &amp; research. 🫀❤️ 😊 #ACC2025 <a href="/ACCinTouch/">American College of Cardiology</a> <a href="/uw_cvm/">UW-Madison Division of Cardiovascular Medicine</a> <a href="/CardioNerds/">CardioNerds</a>
Alfonso Valle (@vallealfonso) 's Twitter Profile Photo

📢🧵Thread: Finerenone in HFpEF & Glycaemic Status 💡 New insights from the FINEARTS-HF trial — published in @EJHeartFailure #CardioTwitter #HeartFailure #Finerenone #HFpEF #Diabetes #MedTwitter 1/🔬 Study: Prespecified analysis of the FINEARTS-HF trial 🧍‍♂️Population: 6001

📢🧵Thread: Finerenone in HFpEF &amp; Glycaemic Status
💡 New insights from the FINEARTS-HF trial — published in @EJHeartFailure
#CardioTwitter #HeartFailure #Finerenone #HFpEF #Diabetes #MedTwitter

1/🔬 Study: Prespecified analysis of the FINEARTS-HF trial
🧍‍♂️Population: 6001
Mariam Ansar (@mariamansar1) 's Twitter Profile Photo

Always love teaching my fellow interns when I’m on CCU week.✨ Grateful to Dr. Thomas and Dr. Lee who gave me the opportunity amidst this busy rotation. Topics discussed throughout the week included RHC, Pressors in ICU/CCU, mixed venous measurements and Ficks equation for

Always love teaching my fellow interns when I’m on CCU week.✨
Grateful to Dr. Thomas and Dr. Lee who gave me the opportunity amidst this busy rotation.

Topics discussed throughout the week included RHC, Pressors in ICU/CCU, mixed venous measurements and Ficks equation for
Mariam Ansar (@mariamansar1) 's Twitter Profile Photo

Lets look at some ACC Late Breaking Trials at a glance🫀 👉API-CAT Trial: Reduced dose of Apixaban is non inferior to full dose in preventing recurrent VTE in patients with Hx of cancer or VTE. Results in lower bleeding risks as well. 👉SMART-CHOICE 3 Trial: Clopidogrel

Lets look at some ACC Late Breaking Trials at a glance🫀

👉API-CAT Trial: 
Reduced dose of Apixaban is non inferior to full dose in preventing recurrent VTE in patients with Hx of cancer or VTE. Results in lower bleeding risks as well.

👉SMART-CHOICE 3 Trial: 
Clopidogrel